Virtus Biotech Clinical Trials ETF
18 hedge funds and large institutions have $16.2M invested in Virtus Biotech Clinical Trials ETF in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
4.92% more ownership
Funds ownership: 36.63% → 41.56% (+4.9%)
5% less funds holding
Funds holding: 19 → 18 (-1)
11% less capital invested
Capital invested by funds: $18.2M → $16.2M (-$2M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.2M |
| 2 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
+$760K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$603K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$437K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$62.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
-$2.06M |
| 2 |
Morgan Stanley
New York
|
-$704K |
| 3 |
LPL Financial
San Diego,
California
|
-$252K |
| 4 |
Bank of New York Mellon
New York
|
-$207K |
| 5 |
OPS
Orion Portfolio Solutions
Omaha,
Nebraska
|
-$138K |
BBC Hedge Fund Activity: Q3 2020 in Review
18 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2020, worth a combined $16.2M — down 11% from $18.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBC and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.
The largest buyer was Susquehanna International Group, adding an estimated $1.2M. The largest seller was Niemann Capital Management, exiting entirely with an estimated $2.06M sold.
- 18 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2020, down from 19 in Q2 2020.
- Funds reported $16.2M of Virtus Biotech Clinical Trials ETF stock for Q3 2020, down 11% quarter-over-quarter.
- 3 funds opened new Virtus Biotech Clinical Trials ETF positions in Q3 2020 and 4 closed out, a net change of -1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2020 was Susquehanna International Group, an estimated $1.2M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q3 2020 was Niemann Capital Management, an estimated $2.06M sold.
Based on aggregated 13F filings for Q3 2020.